94 related articles for article (PubMed ID: 8932351)
1. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy.
Fosså SD; Sternberg C; Scher HI; Theodore CH; Mead B; Dearnaley D; Roberts JT; Skovlund E
Br J Cancer; 1996 Nov; 74(10):1655-9. PubMed ID: 8932351
[TBL] [Abstract][Full Text] [Related]
2. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.
Moschini M; Shariat SF; Rouprêt M; De Santis M; Bellmunt J; Sternberg CN; Tombal B; Collette L
J Urol; 2018 May; 199(5):1149-1157. PubMed ID: 29158104
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up results of a Pilot Phase II study of multidrug chemotherapy (MVP-CAB) in patients with advanced urothelial cancer.
Gohji K; Ono Y; Takenaka A; Nomi M; Okamoto M; Yuen K; Fujii A
Jpn J Clin Oncol; 1999 Apr; 29(4):204-8. PubMed ID: 10340044
[TBL] [Abstract][Full Text] [Related]
4. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
Hibi H; Okamura K; Takashi M; Shimoji T; Miyake K
Hinyokika Kiyo; 1997 Feb; 43(2):89-96. PubMed ID: 9086342
[TBL] [Abstract][Full Text] [Related]
5. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer.
Igawa M; Ohkuchi T; Ueki T; Ueda M; Okada K; Usui T
J Urol; 1990 Sep; 144(3):662-5. PubMed ID: 2388322
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results of methotrexate, etoposide and cisplatin in the treatment of urothelial cancer.
Igawa M; Kadena H; Tacho T; Nakamoto T; Usui T
Urol Int; 1995; 54(2):80-4. PubMed ID: 7747364
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for advanced TCC of urothelium.
Huang CH; Hsieh HH; Wang JM; Hsu K; Yang WC; Yu TJ
J Formos Med Assoc; 1992 Jul; 91(7):699-703. PubMed ID: 1360298
[TBL] [Abstract][Full Text] [Related]
8. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party.
Mead GM; Russell M; Clark P; Harland SJ; Harper PG; Cowan R; Roberts JT; Uscinska BM; Griffiths GO; Parmar MK
Br J Cancer; 1998 Oct; 78(8):1067-75. PubMed ID: 9792152
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
Kuroda M; Kotake T; Akaza H; Hinotsu S; Kakizoe T
Jpn J Clin Oncol; 1998 Aug; 28(8):497-501. PubMed ID: 9769784
[TBL] [Abstract][Full Text] [Related]
11. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin, methotrexate and mitoxantrone in patients with metastatic or advanced urothelial cancer.
Andersen LJ; Sengeløv L; Kamby C; von der Maase H
Acta Oncol; 1998; 37(1):110-2. PubMed ID: 9572664
[No Abstract] [Full Text] [Related]
13. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
[TBL] [Abstract][Full Text] [Related]
14. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
Dodd PM; McCaffrey JA; Herr H; Mazumdar M; Bacik J; Higgins G; Boyle MG; Scher HI; Bajorin DF
J Clin Oncol; 1999 Aug; 17(8):2546-52. PubMed ID: 10561321
[TBL] [Abstract][Full Text] [Related]
15. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract.
Igawa M; Urakami S; Shiina H; Kishi H; Himeno Y; Ishibe T; Kadena H; Usui T
Urol Int; 1995; 55(2):74-7. PubMed ID: 8533199
[TBL] [Abstract][Full Text] [Related]
17. [Investigation of postoperative adjuvant chemotherapy in patients with transitional cell carcinoma of the upper urothelium. Nara Urooncology Research Group (NUORG)].
Uemura H; Ozono S; Hayashi Y; Hirao Y; Okajima E; Aoyoma H; Sasaki K; Ohara S; Hashimoto M; Yoshikawa M
Nihon Hinyokika Gakkai Zasshi; 1991 Aug; 82(8):1273-80. PubMed ID: 1921019
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
Siefker-Radtke AO; Millikan RE; Tu SM; Moore DF; Smith TL; Williams D; Logothetis CJ
J Clin Oncol; 2002 Mar; 20(5):1361-7. PubMed ID: 11870180
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy.
Jessen C; Agerbaek M; Von Der Maase H
Acta Oncol; 2009; 48(3):411-7. PubMed ID: 18798018
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
